Sign In

Login

Password

Forgot Password ? Sign Up

Mięsak Kaposiego (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mięsak Kaposiego" in Polish language version.

refsWebsite
Global rank Polish rank
105nih.gov
4th place
7th place
71doi.org
2nd place
6th place
7google.pl
low place
557th place
5web.archive.org
1st place
1st place
2onkologia.org.pl
low place
8,813th place
1archivesofpathology.org
low place
low place
1who.int
195th place
256th place
1iarc.fr
4,025th place
low place
1europeanreview.org
low place
low place
1cancer.org
3,680th place
6,345th place
1yhscn.nhs.uk
low place
low place
1omicsonline.org
low place
low place
1medcomhk.com
low place
low place

archivesofpathology.org

cancer.org

doi.org

  • T. Vogt, N. Brockmeyer, H. Kutzner, H. Schöfer. Brief S1 guidelines-Cutaneous angiosarcoma and Kaposi sarcoma. „J Dtsch Dermatol Ges”. 11 Suppl 3, 2013. DOI: 10.1111/ddg.12015_2. PMID: 23734888. 
  • O. Radu, L. Pantanowitz. Kaposi sarcoma. „Arch Pathol Lab Med”. 137 (2), s. 289–294, Feb 2013. DOI: 10.5858/arpa.2012-0101-RS. PMID: 23368874. 
  • C.S. Restrepo, S. Martínez, J.A. Lemos, J.A. Carrillo i inni. Imaging manifestations of Kaposi sarcoma. „Radiographics”. 26 (4). s. 1169–1185. DOI: 10.1148/rg.264055129. PMID: 16844940. 
  • R.A. Schwartz, G. Micali, M.R. Nasca, L. Scuderi. Kaposi sarcoma: a continuing conundrum. „J Am Acad Dermatol”. 59 (2), s. 179–206, 2008. DOI: 10.1016/j.jaad.2008.05.001. PMID: 18638627. 
  • G. Zavos, J. Bokos, I. Papaconstantinou, J. Boletis i inni. Clinicopathological aspects of 18 Kaposi’s sarcoma among 1055 Greek renal transplant recipients. „Artif Organs”. 28 (6), s. 595–599, 2004. DOI: 10.1111/j.1525-1594.2004.00019.x. PMID: 15153155. 
  • C. Lebbé, C. Legendre, C. Francès. Kaposi sarcoma in transplantation. „Transplant Rev (Orlando)”. 22 (4), s. 252–261, 2008. DOI: 10.1016/j.trre.2008.05.004. PMID: 18656341. 
  • C.A. Stiller, A. Trama, D.H. Brewster, J. Verne i inni. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. „Cancer Epidemiol”. 38 (6), s. 670–678, 2014. DOI: 10.1016/j.canep.2014.09.009. PMID: 25454979. 
  • L. Dal Maso, J. Polesel, V. Ascoli, P. Zambon i inni. Classic Kaposi’s sarcoma in Italy, 1985-1998. „Br J Cancer”. 92 (1), s. 188–193, 2005. DOI: 10.1038/sj.bjc.6602265. PMID: 15570306. 
  • E. Guttman-Yassky, M. Bar-Chana, A. Yukelson, S. Linn i inni. Epidemiology of classic Kaposi’s sarcoma in the Israeli Jewish population between 1960 and 1998. „Br J Cancer”. 89 (9), s. 1657–1660, 2003. DOI: 10.1038/sj.bjc.6601313. PMID: 14583765. 
  • M.S. Shiels, E.A. Engels. Evolving epidemiology of HIV-associated malignancies. „Curr Opin HIV AIDS”, 2016. DOI: 10.1097/COH.0000000000000327. PMID: 27749369. 
  • H.R. Wabinga, D.M. Parkin, F. Wabwire-Mangen, S. Nambooze. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. „Br J Cancer”. 82 (9), s. 1585–1592, 2000. DOI: 10.1054/bjoc.1999.1071. PMID: 10789729. 
  • A.W. Armstrong, K.H. Lam, E.P. Chase. Epidemiology of classic and AIDS-related Kaposi’s sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. „Epidemiol Infect”. 141 (1), s. 200–206, Jan 2013. DOI: 10.1017/S0950268812000325. PMID: 22404880. 
  • S. Portsmouth, J. Stebbing, J. Gill, S. Mandalia i inni. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. „AIDS”. 17 (11), s. 17–22, Jul 2003. DOI: 10.1097/01.aids.0000076309.76477.f1. PMID: 12853764. 
  • W. Grayson, L. Pantanowitz. Histological variants of cutaneous Kaposi sarcoma. „Diagn Pathol”. 3, s. 31, 2008. DOI: 10.1186/1746-1596-3-31. PMID: 18655700. 
  • L. Hammock, A. Reisenauer, W. Wang, C. Cohen i inni. Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients. „Mod Pathol”. 18 (4), s. 463–468, 2005. DOI: 10.1038/modpathol.3800221. PMID: 15578080. 
  • R.M. Patel, J.R. Goldblum, E.D. Hsi. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. „Mod Pathol”. 17 (4), s. 456–460, 2004. DOI: 10.1038/modpathol.3800061. PMID: 14990970. 
  • L.E. Cavallin, P. Goldschmidt-Clermont, E.A. Mesri. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi’s sarcoma associated with HIV/AIDS. „PLoS Pathog”. 10 (7), 2014. DOI: 10.1371/journal.ppat.1004154. PMID: 25010730. 
  • H.W. Wang, M.W. Trotter, D. Lagos, D. Bourboulia i inni. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. „Nat Genet”. 36 (7), s. 687–693, 2004. DOI: 10.1038/ng1384. PMID: 15220918. 
  • R.J. Biggar, A.K. Chaturvedi, J.J. Goedert, E.A. Engels. AIDS-related cancer and severity of immunosuppression in persons with AIDS. „J Natl Cancer Inst”. 99 (12), s. 962–972, 2007. DOI: 10.1093/jnci/djm010. PMID: 17565153. 
  • T.S. Uldrick, D. Whitby. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. „Cancer Lett”. 305 (2), s. 150–162, 2011. DOI: 10.1016/j.canlet.2011.02.006. PMID: 21377267. 
  • E.E. Brown, D. Whitby, F. Vitale, V. Marshall i inni. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. „Cancer”. 107 (9), s. 2282–2290, 2006. DOI: 10.1002/cncr.22236. PMID: 16998933. 
  • A. Guihot, N. Dupin, A.G. Marcelin, I. Gorin i inni. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. „J Infect Dis”. 194 (8), s. 1078–1088, 2006. DOI: 10.1086/507648. PMID: 16991082. 
  • F. Bihl, A. Mosam, L.N. Henry, J.V. Chisholm i inni. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. „AIDS”. 21 (10), s. 1245–1252, 2007. DOI: 10.1097/QAD.0b013e328182df03. PMID: 17545700. 
  • E. Ruocco, V. Ruocco, M.L. Tornesello, A. Gambardella i inni. Kaposi’s sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. „Clin Dermatol”. 31 (4). s. 413–422. DOI: 10.1016/j.clindermatol.2013.01.008. PMID: 23806158. 
  • F.M. Buonaguro, M.L. Tornesello, E. Beth-Giraldo, A. Hatzakis i inni. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. „Int J Cancer”. 65 (1), s. 25–28, 1996. DOI: <25::AID-IJC5>3.0.CO;2-3 10.1002/(SICI)1097-0215(19960103)65:1<25::AID-IJC5>3.0.CO;2-3. PMID: 8543391. 
  • D. Ganem. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. „J Clin Invest”. 120 (4), s. 939–949, 2010. DOI: 10.1172/JCI40567. PMID: 20364091. 
  • G.R. Simpson, T.F. Schulz, D. Whitby, P.M. Cook i inni. Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. „Lancet”. 348 (9035), s. 1133–1138, 1996. DOI: 10.1016/S0140-6736(96)07560-5. PMID: 8888167. 
  • R.J. Sullivan, L. Pantanowitz, C. Casper, J. Stebbing i inni. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. „Clin Infect Dis”. 47 (9), s. 1209–1215, 2008. DOI: 10.1086/592298. PMID: 18808357. 
  • J. Friborg, W. Kong, M.O. Hottiger, G.J. Nabel. p53 inhibition by the LANA protein of KSHV protects against cell death. „Nature”. 402 (6764). s. 889–894. DOI: 10.1038/47266. PMID: 10622254. 
  • S.A. Radkov, P. Kellam, C. Boshoff. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. „Nat Med”. 6 (10), s. 1121–1127, 2000. DOI: 10.1038/80459. PMID: 11017143. 
  • M. Fujimuro, F.Y. Wu, C. ApRhys, H. Kajumbula i inni. A novel viral mechanism for dysregulation of beta-catenin in Kaposi’s sarcoma-associated herpesvirus latency. „Nat Med”. 9 (3), s. 300–306, 2003. DOI: 10.1038/nm829. PMID: 12592400. 
  • D.F. Martin, B.D. Kuppermann, R.A. Wolitz, A.G. Palestine i inni. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. „N Engl J Med”. 340 (14), s. 1063–1070, 1999. DOI: 10.1056/NEJM199904083401402. PMID: 10194235. 
  • A. Sodhi, S. Montaner, J.S. Gutkind. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi’s sarcomagenesis?. „FASEB J”. 18 (3), s. 422–427, 2004. DOI: 10.1096/fj.03-1035hyp. PMID: 15003988. 
  • R. Sullivan, B.J. Dezube, H.B. Koon. Signal transduction targets in Kaposi’s sarcoma. „Curr Opin Oncol”. 18 (5), s. 456–462, 2006. DOI: 10.1097/01.cco.0000239884.05914.13. PMID: 16894293. 
  • Q. Sun, S. Zachariah, P.M. Chaudhary. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. „J Biol Chem”. 278 (52), 2003. DOI: 10.1074/jbc.M304199200. PMID: 14563855. 
  • L. Feller, J. Lemmer. Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma. „Infect Agent Cancer”. 3, s. 1, 2008. DOI: 10.1186/1750-9378-3-1. PMID: 18208585. 
  • P. Curtiss, L.C. Strazzulla, A.E. Friedman-Kien. An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment. „Dermatol Ther (Heidelb)”. 6 (4), s. 465–470, 2016. DOI: 10.1007/s13555-016-0152-3. PMID: 27804093. 
  • L. Feller, N.H. Wood, J. Lemmer. HIV-associated Kaposi sarcoma: pathogenic mechanisms. „Oral Surg Oral Med Oral Pathol Oral Radiol Endod”. 104 (4), s. 521–519, 2007. DOI: 10.1016/j.tripleo.2006.08.015. PMID: 17142074. 
  • M. Bower, A. Palfreeman, M. Alfa-Wali, C. Bunker i inni. British HIV Association guidelines for HIV-associated malignancies 2014. „HIV Med”. 15 Suppl 2, s. 1–92, 2014. DOI: 10.1111/hiv.12136. PMID: 24528810. 
  • R. Snodgrass, A. Gardner, L. Jiang, C. Fu i inni. KS-Detect – Validation of Solar Thermal PCR for the Diagnosis of Kaposi’s Sarcoma Using Pseudo-Biopsy Samples. „PLoS One”. 11 (1), 2016. DOI: 10.1371/journal.pone.0147636. PMID: 26799834. 
  • E. Amerson, C.M. Woodruff, A. Forrestel, M. Wenger i inni. Accuracy of Clinical Suspicion and Pathologic Diagnosis of Kaposi Sarcoma in East Africa. „J Acquir Immune Defic Syndr”. 71 (3), s. 295–301, 2016. DOI: 10.1097/QAI.0000000000000862. PMID: 26452066. 
  • L.J. van Bogaert. Clinicopathological Proficiency in the Diagnosis of Kaposi’s Sarcoma. „ISRN AIDS”. 2012, 2012. DOI: 10.5402/2012/565463. PMID: 24052878. 
  • X. García del Muro Solans, J. Martín Broto, P. Lianes Barragán, R. Cubedo Cervera. SEOM clinical guidelines for the management of adult soft tissue sarcomas. „Clin Transl Oncol”. 14 (7), s. 541–544, 2012. DOI: 10.1007/s12094-012-0838-7. PMID: 22721800. 
  • S.E. Krown. Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma. „J Clin Oncol”. 22 (3), s. 399–402, 2004. DOI: 10.1200/JCO.2004.08.064. PMID: 14752065. 
  • M. Bower, J. Weir, N. Francis, T. Newsom-Davis i inni. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. „AIDS”. 23 (13), s. 1701–1706, 2009. DOI: 10.1097/QAD.0b013e32832d080d. PMID: 19550283. 
  • B. Holkova, K. Takeshita, D.M. Cheng, M. Volm i inni. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated with chemotherapy. „J Clin Oncol”. 19 (18), s. 3848–3851, 2001. DOI: 10.1200/jco.2001.19.18.3848. PMID: 11559722. 
  • L. Dal Maso, J. Polesel, D. Serraino, M. Lise i inni. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. „Br J Cancer”. 100 (5), s. 840–847, 2009. DOI: 10.1038/sj.bjc.6604923. PMID: 19223894. 
  • E.C. Seaberg, D. Wiley, O. Martínez-Maza, J.S. Chmiel i inni. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. „Cancer”. 116 (23), s. 5507–5516, 2010. DOI: 10.1002/cncr.25530. PMID: 20672354. 
  • H.W. Jaffe, B.L. De Stavola, L.M. Carpenter, K. Porter i inni. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. „AIDS”. 25 (11), s. 1395–1403, 2011. DOI: 10.1097/QAD.0b013e3283489c8b. PMID: 21572307. 
  • M. Bower, M. Nelson, A.M. Young, C. Thirlwell i inni. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. „J Clin Oncol”. 23 (22), s. 5224–5228, 2005. DOI: 10.1200/JCO.2005.14.597. PMID: 16051964. 
  • C.J. Achenbach, R.D. Harrington, S. Dhanireddy, H.M. Crane i inni. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. „Clin Infect Dis”. 54 (3), s. 424–433, 2012. DOI: 10.1093/cid/cir802. PMID: 22095568. 
  • R.S. Leidner, D.M. Aboulafia. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. „AIDS Patient Care STDS”. 19 (10), s. 635–644, 2005. DOI: 10.1089/apc.2005.19.635. PMID: 16232048. 
  • E. Régnier-Rosencher, B. Guillot, N. Dupin. Treatments for classic Kaposi sarcoma: a systematic review of the literature. „J Am Acad Dermatol”. 68 (2), s. 313–331, 2013. DOI: 10.1016/j.jaad.2012.04.018. PMID: 22695100. 
  • S.M. Rafiyath, M. Rasul, B. Lee, G. Wei i inni. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. „Exp Hematol Oncol”. 1 (1), s. 10, 2012. DOI: 10.1186/2162-3619-1-10. PMID: 23210520. 
  • D.W. Northfelt, B.J. Dezube, J.A. Thommes, B.J. Miller i inni. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. „J Clin Oncol”. 16 (7), s. 2445–2451, 1998. DOI: 10.1200/jco.1998.16.7.2445. PMID: 9667262. 
  • S. Stewart, H. Jablonowski, F.D. Goebel, K. Arasteh i inni. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. „J Clin Oncol”. 16 (2), s. 683–691, 1998. DOI: 10.1200/jco.1998.16.2.683. PMID: 9469358. 
  • P.S. Gill, J. Wernz, D.T. Scadden, P. Cohen i inni. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. „J Clin Oncol”. 14 (8), s. 2353–2364, 1996. DOI: 10.1200/jco.1996.14.8.2353. PMID: 8708728. 
  • T. Cooley, D. Henry, M. Tonda, S. Sun i inni. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. „Oncologist”. 12 (1), s. 114–123, 2007. DOI: 10.1634/theoncologist.12-1-114. PMID: 17227906. 
  • P.S. Gill, A. Tulpule, B.M. Espina, S. Cabriales i inni. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. „J Clin Oncol”. 17 (6), s. 1876–1883, 1999. DOI: 10.1200/jco.1999.17.6.1876. PMID: 10561228. 
  • L. Welles, M.W. Saville, J. Lietzau, J.M. Pluda i inni. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. „J Clin Oncol”. 16 (3), s. 1112–1121, 1998. DOI: 10.1200/jco.1998.16.3.1112. PMID: 9508198. 
  • M. Cianfrocca, S. Lee, J. Von Roenn, A. Tulpule i inni. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. „Cancer”. 116 (16), s. 3969–3977, 2010. DOI: 10.1002/cncr.25362. PMID: 20564162. 
  • J. Autier, C. Picard-Dahan, E. Marinho, M. Grossin i inni. Docetaxel in anthracycline-pretreated AIDS-related Kaposi’s sarcoma: a retrospective study. „Br J Dermatol”. 152 (5), s. 1026–1029, 2005. DOI: 10.1111/j.1365-2133.2005.06452.x. PMID: 15888164. 
  • S.T. Lim, A. Tupule, B.M. Espina, A.M. Levine. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. „Cancer”. 103 (2), s. 417–421, 2005. DOI: 10.1002/cncr.20780. PMID: 15578686. 
  • S.E. Krown, P. Li, J.H. Von Roenn, J. Paredes i inni. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi’s sarcoma: a randomized phase II AIDS clinical trials group study. „J Interferon Cytokine Res”. 22 (3), s. 295–303, 2002. DOI: 10.1089/107999002753675712. PMID: 12034036. 
  • F.A. Shepherd, R. Beaulieu, K. Gelmon, C.A. Thuot i inni. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. „J Clin Oncol”. 16 (5), s. 1736–1742, 1998. DOI: 10.1200/jco.1998.16.5.1736. PMID: 9586886. 
  • A. Kreuter, H. Rasokat, M. Klouche, S. Esser i inni. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi’s sarcoma; retrospective analysis of three German centers. „Cancer Invest”. 23 (8), s. 653–659, 2005. DOI: 10.1080/07357900500358259. PMID: 16377582. 
  • G. Di Lorenzo, A. Kreuter, R. Di Trolio, A. Guarini i inni. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi’s sarcoma: a multicenter study. „J Invest Dermatol”. 128 (6), s. 1578–1580, 2008. DOI: 10.1038/sj.jid.5701215. PMID: 18185536. 
  • G. Di Lorenzo. Update on classic Kaposi sarcoma therapy: new look at an old disease. „Crit Rev Oncol Hematol”. 68 (3), s. 242–249, 2008. DOI: 10.1016/j.critrevonc.2008.06.007. PMID: 18657433. 
  • L. Brambilla, A. Romanelli, M. Bellinvia, S. Ferrucci i inni. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. „Br J Dermatol”. 158 (6), s. 1339–1344, 2008. DOI: 10.1111/j.1365-2133.2008.08517.x. PMID: 18363766. 
  • L. Fardet, P.E. Stoebner, H. Bachelez, V. Descamps i inni. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. „Cancer”. 106 (8), s. 1785–1789, 2006. DOI: 10.1002/cncr.21791. PMID: 16534786. 
  • G. Stallone, A. Schena, B. Infante, S. Di Paolo i inni. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. „N Engl J Med”. 352 (13), s. 1317–1323, 2005. DOI: 10.1056/NEJMoa042831. PMID: 15800227. 

europeanreview.org

google.pl

books.google.pl

iarc.fr

globocan.iarc.fr

medcomhk.com

nih.gov

ncbi.nlm.nih.gov

  • T. Vogt, N. Brockmeyer, H. Kutzner, H. Schöfer. Brief S1 guidelines-Cutaneous angiosarcoma and Kaposi sarcoma. „J Dtsch Dermatol Ges”. 11 Suppl 3, 2013. DOI: 10.1111/ddg.12015_2. PMID: 23734888. 
  • O. Radu, L. Pantanowitz. Kaposi sarcoma. „Arch Pathol Lab Med”. 137 (2), s. 289–294, Feb 2013. DOI: 10.5858/arpa.2012-0101-RS. PMID: 23368874. 
  • C.S. Restrepo, S. Martínez, J.A. Lemos, J.A. Carrillo i inni. Imaging manifestations of Kaposi sarcoma. „Radiographics”. 26 (4). s. 1169–1185. DOI: 10.1148/rg.264055129. PMID: 16844940. 
  • R.A. Schwartz, G. Micali, M.R. Nasca, L. Scuderi. Kaposi sarcoma: a continuing conundrum. „J Am Acad Dermatol”. 59 (2), s. 179–206, 2008. DOI: 10.1016/j.jaad.2008.05.001. PMID: 18638627. 
  • A. Weissmann, S. Linn, S. Weltfriend, R. Friedman-Birnbaum. Epidemiological study of classic Kaposi’s sarcoma: a retrospective review of 125 cases from Northern Israel. „J Eur Acad Dermatol Venereol”. 14 (2), s. 91–95, 2000. PMID: 10972092. 
  • B. Safai, K.G. Johnson, P.L. Myskowski, B. Koziner i inni. The natural history of Kaposi’s sarcoma in the acquired immunodeficiency syndrome. „Ann Intern Med”. 103 (5), s. 744–750, 1985. PMID: 3901851. 
  • M.H. Katz, N.A. Hessol, S.P. Buchbinder, A. Hirozawa i inni. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. „J Infect Dis”. 170 (1), s. 198–202, 1994. PMID: 8014498. 
  • V. Beral, T.A. Peterman, R.L. Berkelman, H.W. Jaffe. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection?. „Lancet”. 335 (8682), s. 123–128, 1990. PMID: 1967430. 
  • G.W. Niedt, R.A. Schinella. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. „Arch Pathol Lab Med”. 109 (8), s. 727–734, 1985. PMID: 2990378. 
  • M.E. Stein, D. Spencer, P. Ruff. Lymphoproliferative malignancies in association with endemic African Kaposi’s sarcoma. „Cent Afr J Med”. 40 (7), s. 176–178, 1994. PMID: 7812990. 
  • G. Zavos, J. Bokos, I. Papaconstantinou, J. Boletis i inni. Clinicopathological aspects of 18 Kaposi’s sarcoma among 1055 Greek renal transplant recipients. „Artif Organs”. 28 (6), s. 595–599, 2004. DOI: 10.1111/j.1525-1594.2004.00019.x. PMID: 15153155. 
  • C. Lebbé, C. Legendre, C. Francès. Kaposi sarcoma in transplantation. „Transplant Rev (Orlando)”. 22 (4), s. 252–261, 2008. DOI: 10.1016/j.trre.2008.05.004. PMID: 18656341. 
  • C.A. Stiller, A. Trama, D.H. Brewster, J. Verne i inni. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. „Cancer Epidemiol”. 38 (6), s. 670–678, 2014. DOI: 10.1016/j.canep.2014.09.009. PMID: 25454979. 
  • L. Dal Maso, J. Polesel, V. Ascoli, P. Zambon i inni. Classic Kaposi’s sarcoma in Italy, 1985-1998. „Br J Cancer”. 92 (1), s. 188–193, 2005. DOI: 10.1038/sj.bjc.6602265. PMID: 15570306. 
  • E. Guttman-Yassky, M. Bar-Chana, A. Yukelson, S. Linn i inni. Epidemiology of classic Kaposi’s sarcoma in the Israeli Jewish population between 1960 and 1998. „Br J Cancer”. 89 (9), s. 1657–1660, 2003. DOI: 10.1038/sj.bjc.6601313. PMID: 14583765. 
  • M.S. Shiels, E.A. Engels. Evolving epidemiology of HIV-associated malignancies. „Curr Opin HIV AIDS”, 2016. DOI: 10.1097/COH.0000000000000327. PMID: 27749369. 
  • H.R. Wabinga, D.M. Parkin, F. Wabwire-Mangen, S. Nambooze. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. „Br J Cancer”. 82 (9), s. 1585–1592, 2000. DOI: 10.1054/bjoc.1999.1071. PMID: 10789729. 
  • A.W. Armstrong, K.H. Lam, E.P. Chase. Epidemiology of classic and AIDS-related Kaposi’s sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. „Epidemiol Infect”. 141 (1), s. 200–206, Jan 2013. DOI: 10.1017/S0950268812000325. PMID: 22404880. 
  • L. La Ferla, M.R. Pinzone, G. Nunnari, F. Martellotta i inni. Kaposi’s sarcoma in HIV-positive patients: the state of art in the HAART-era. „Eur Rev Med Pharmacol Sci”. 17 (17), s. 2354–2365, 2013. PMID: 24065230. [zarchiwizowane z adresu 2018-05-10]. 
  • D.M. Aboulafia. The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi’s sarcoma. „Chest”. 117 (4), s. 1128–1145, 2000. PMID: 10767252. 
  • S. Portsmouth, J. Stebbing, J. Gill, S. Mandalia i inni. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. „AIDS”. 17 (11), s. 17–22, Jul 2003. DOI: 10.1097/01.aids.0000076309.76477.f1. PMID: 12853764. 
  • B.J. Dezube. Clinical presentation and natural history of AIDS-related Kaposi’s sarcoma. „Hematol Oncol Clin North Am”. 10 (5), s. 1023–1029, 1996. PMID: 8880194. 
  • D.R. Gnepp, W. Chandler, V. Hyams. Primary Kaposi’s sarcoma of the head and neck. „Ann Intern Med”. 100 (1), s. 107–114, 1984. PMID: 6362509. 
  • B. Singh, G. Har-el, F.E. Lucente. Kaposi’s sarcoma of the head and neck in patients with acquired immunodeficiency syndrome. „Otolaryngol Head Neck Surg”. 111 (5), s. 618–624, 1994. PMID: 7970801. 
  • W. Grayson, L. Pantanowitz. Histological variants of cutaneous Kaposi sarcoma. „Diagn Pathol”. 3, s. 31, 2008. DOI: 10.1186/1746-1596-3-31. PMID: 18655700. 
  • L. Hammock, A. Reisenauer, W. Wang, C. Cohen i inni. Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients. „Mod Pathol”. 18 (4), s. 463–468, 2005. DOI: 10.1038/modpathol.3800221. PMID: 15578080. 
  • R.M. Patel, J.R. Goldblum, E.D. Hsi. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. „Mod Pathol”. 17 (4), s. 456–460, 2004. DOI: 10.1038/modpathol.3800061. PMID: 14990970. 
  • J.L. Douglas, J.K. Gustin, A.V. Moses, B.J. Dezube i inni. Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation. „Transl Biomed”. 1 (2), 2010. PMID: 23082307. 
  • L.E. Cavallin, P. Goldschmidt-Clermont, E.A. Mesri. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi’s sarcoma associated with HIV/AIDS. „PLoS Pathog”. 10 (7), 2014. DOI: 10.1371/journal.ppat.1004154. PMID: 25010730. 
  • H.W. Wang, M.W. Trotter, D. Lagos, D. Bourboulia i inni. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. „Nat Genet”. 36 (7), s. 687–693, 2004. DOI: 10.1038/ng1384. PMID: 15220918. 
  • R.J. Biggar, A.K. Chaturvedi, J.J. Goedert, E.A. Engels. AIDS-related cancer and severity of immunosuppression in persons with AIDS. „J Natl Cancer Inst”. 99 (12), s. 962–972, 2007. DOI: 10.1093/jnci/djm010. PMID: 17565153. 
  • T.S. Uldrick, D. Whitby. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. „Cancer Lett”. 305 (2), s. 150–162, 2011. DOI: 10.1016/j.canlet.2011.02.006. PMID: 21377267. 
  • E.E. Brown, D. Whitby, F. Vitale, V. Marshall i inni. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. „Cancer”. 107 (9), s. 2282–2290, 2006. DOI: 10.1002/cncr.22236. PMID: 16998933. 
  • A. Guihot, N. Dupin, A.G. Marcelin, I. Gorin i inni. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. „J Infect Dis”. 194 (8), s. 1078–1088, 2006. DOI: 10.1086/507648. PMID: 16991082. 
  • F. Bihl, A. Mosam, L.N. Henry, J.V. Chisholm i inni. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. „AIDS”. 21 (10), s. 1245–1252, 2007. DOI: 10.1097/QAD.0b013e328182df03. PMID: 17545700. 
  • E. Ruocco, V. Ruocco, M.L. Tornesello, A. Gambardella i inni. Kaposi’s sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. „Clin Dermatol”. 31 (4). s. 413–422. DOI: 10.1016/j.clindermatol.2013.01.008. PMID: 23806158. 
  • Y. Chang, E. Cesarman, M.S. Pessin, F. Lee i inni. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. „Science”. 266 (5192), s. 1865–1869, 1994. PMID: 7997879. 
  • F.M. Buonaguro, M.L. Tornesello, E. Beth-Giraldo, A. Hatzakis i inni. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. „Int J Cancer”. 65 (1), s. 25–28, 1996. DOI: <25::AID-IJC5>3.0.CO;2-3 10.1002/(SICI)1097-0215(19960103)65:1<25::AID-IJC5>3.0.CO;2-3. PMID: 8543391. 
  • P.S. Moore, L.A. Kingsley, S.D. Holmberg, T. Spira i inni. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. „AIDS”. 10 (2), s. 175–180, 1996. PMID: 8838705. 
  • D. Ganem. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. „J Clin Invest”. 120 (4), s. 939–949, 2010. DOI: 10.1172/JCI40567. PMID: 20364091. 
  • S.J. Gao, L. Kingsley, M. Li, W. Zheng i inni. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. „Nat Med”. 2 (8), s. 925–958, 1996. PMID: 8705864. 
  • T.F. Schulz. Epidemiology of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. „Adv Cancer Res”. 76, s. 121–160, 1999. PMID: 10218100. 
  • C. Casper, M. Redman, M.L. Huang, J. Pauk i inni. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. „J Acquir Immune Defic Syndr”. 35 (3), s. 233–238, 2004. PMID: 15076237. 
  • G.R. Simpson, T.F. Schulz, D. Whitby, P.M. Cook i inni. Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. „Lancet”. 348 (9035), s. 1133–1138, 1996. DOI: 10.1016/S0140-6736(96)07560-5. PMID: 8888167. 
  • D.H. Kedes, E. Operskalski, M. Busch, R. Kohn i inni. The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. „Nat Med”. 2 (8), s. 918–924, 1996. PMID: 8705863. 
  • R.J. Sullivan, L. Pantanowitz, C. Casper, J. Stebbing i inni. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. „Clin Infect Dis”. 47 (9), s. 1209–1215, 2008. DOI: 10.1086/592298. PMID: 18808357. 
  • J. Friborg, W. Kong, M.O. Hottiger, G.J. Nabel. p53 inhibition by the LANA protein of KSHV protects against cell death. „Nature”. 402 (6764). s. 889–894. DOI: 10.1038/47266. PMID: 10622254. 
  • S.A. Radkov, P. Kellam, C. Boshoff. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. „Nat Med”. 6 (10), s. 1121–1127, 2000. DOI: 10.1038/80459. PMID: 11017143. 
  • M. Fujimuro, F.Y. Wu, C. ApRhys, H. Kajumbula i inni. A novel viral mechanism for dysregulation of beta-catenin in Kaposi’s sarcoma-associated herpesvirus latency. „Nat Med”. 9 (3), s. 300–306, 2003. DOI: 10.1038/nm829. PMID: 12592400. 
  • D.F. Martin, B.D. Kuppermann, R.A. Wolitz, A.G. Palestine i inni. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. „N Engl J Med”. 340 (14), s. 1063–1070, 1999. DOI: 10.1056/NEJM199904083401402. PMID: 10194235. 
  • A. Sodhi, S. Montaner, J.S. Gutkind. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi’s sarcomagenesis?. „FASEB J”. 18 (3), s. 422–427, 2004. DOI: 10.1096/fj.03-1035hyp. PMID: 15003988. 
  • R. Sullivan, B.J. Dezube, H.B. Koon. Signal transduction targets in Kaposi’s sarcoma. „Curr Opin Oncol”. 18 (5), s. 456–462, 2006. DOI: 10.1097/01.cco.0000239884.05914.13. PMID: 16894293. 
  • Q. Sun, S. Zachariah, P.M. Chaudhary. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. „J Biol Chem”. 278 (52), 2003. DOI: 10.1074/jbc.M304199200. PMID: 14563855. 
  • L. Feller, J. Lemmer. Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma. „Infect Agent Cancer”. 3, s. 1, 2008. DOI: 10.1186/1750-9378-3-1. PMID: 18208585. 
  • P. Curtiss, L.C. Strazzulla, A.E. Friedman-Kien. An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment. „Dermatol Ther (Heidelb)”. 6 (4), s. 465–470, 2016. DOI: 10.1007/s13555-016-0152-3. PMID: 27804093. 
  • L. Feller, N.H. Wood, J. Lemmer. HIV-associated Kaposi sarcoma: pathogenic mechanisms. „Oral Surg Oral Med Oral Pathol Oral Radiol Endod”. 104 (4), s. 521–519, 2007. DOI: 10.1016/j.tripleo.2006.08.015. PMID: 17142074. 
  • E. Toschi, G. Barillari, C. Sgadari, I. Bacigalupo i inni. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. „Mol Biol Cell”. 12 (10), s. 2934–2946, 2001. PMID: 11598182. 
  • P.C. Brooks, S. Strömblad, L.C. Sanders, T.L. von Schalscha i inni. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. „Cell”. 85 (5), s. 683–693, 1996. PMID: 8646777. 
  • M. Bower, A. Palfreeman, M. Alfa-Wali, C. Bunker i inni. British HIV Association guidelines for HIV-associated malignancies 2014. „HIV Med”. 15 Suppl 2, s. 1–92, 2014. DOI: 10.1111/hiv.12136. PMID: 24528810. 
  • R. Snodgrass, A. Gardner, L. Jiang, C. Fu i inni. KS-Detect – Validation of Solar Thermal PCR for the Diagnosis of Kaposi’s Sarcoma Using Pseudo-Biopsy Samples. „PLoS One”. 11 (1), 2016. DOI: 10.1371/journal.pone.0147636. PMID: 26799834. 
  • E. Amerson, C.M. Woodruff, A. Forrestel, M. Wenger i inni. Accuracy of Clinical Suspicion and Pathologic Diagnosis of Kaposi Sarcoma in East Africa. „J Acquir Immune Defic Syndr”. 71 (3), s. 295–301, 2016. DOI: 10.1097/QAI.0000000000000862. PMID: 26452066. 
  • L.J. van Bogaert. Clinicopathological Proficiency in the Diagnosis of Kaposi’s Sarcoma. „ISRN AIDS”. 2012, 2012. DOI: 10.5402/2012/565463. PMID: 24052878. 
  • CDR0000062914. W: Kaposi Sarcoma Treatment (PDQ®): Health Professional Version. National Cancer Institute (US), 2002. (ang.).
  • X. García del Muro Solans, J. Martín Broto, P. Lianes Barragán, R. Cubedo Cervera. SEOM clinical guidelines for the management of adult soft tissue sarcomas. „Clin Transl Oncol”. 14 (7), s. 541–544, 2012. DOI: 10.1007/s12094-012-0838-7. PMID: 22721800. 
  • S. Walmsley, D.W. Northfelt, B. Melosky, M. Conant i inni. Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. „J Acquir Immune Defic Syndr”. 22 (3), s. 235–246, 1999. PMID: 10770343. 
  • N.J. Bodsworth, M. Bloch, M. Bower, D. Donnell i inni. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi’s sarcoma. „Am J Clin Dermatol”. 2 (2), s. 77–87, 2001. PMID: 11705307. 
  • M. Harrison, K.J. Harrington, D.R. Tomlinson, J.S. Stewart. Response and cosmetic outcome of two fractionation regimens for AIDS-related Kaposi’s sarcoma. „Radiother Oncol”. 46 (1), s. 23–28, 1998. PMID: 9488123. 
  • E.L. Gressen, J.G. Rosenstock, Y. Xie, B.W. Corn. Palliative treatment of epidemic Kaposi sarcoma of the feet. „Am J Clin Oncol”. 22 (3), s. 286–290, 1999. PMID: 10362338. 
  • S.E. Krown. Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma. „J Clin Oncol”. 22 (3), s. 399–402, 2004. DOI: 10.1200/JCO.2004.08.064. PMID: 14752065. 
  • M. Bower, J. Weir, N. Francis, T. Newsom-Davis i inni. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. „AIDS”. 23 (13), s. 1701–1706, 2009. DOI: 10.1097/QAD.0b013e32832d080d. PMID: 19550283. 
  • M. Bower, P. Fox, K. Fife, J. Gill i inni. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. „AIDS”. 13 (15), s. 2105–2111, 1999. PMID: 10546864. 
  • B. Holkova, K. Takeshita, D.M. Cheng, M. Volm i inni. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated with chemotherapy. „J Clin Oncol”. 19 (18), s. 3848–3851, 2001. DOI: 10.1200/jco.2001.19.18.3848. PMID: 11559722. 
  • L. Dal Maso, J. Polesel, D. Serraino, M. Lise i inni. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. „Br J Cancer”. 100 (5), s. 840–847, 2009. DOI: 10.1038/sj.bjc.6604923. PMID: 19223894. 
  • E.C. Seaberg, D. Wiley, O. Martínez-Maza, J.S. Chmiel i inni. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. „Cancer”. 116 (23), s. 5507–5516, 2010. DOI: 10.1002/cncr.25530. PMID: 20672354. 
  • H.W. Jaffe, B.L. De Stavola, L.M. Carpenter, K. Porter i inni. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. „AIDS”. 25 (11), s. 1395–1403, 2011. DOI: 10.1097/QAD.0b013e3283489c8b. PMID: 21572307. 
  • M. Bower, M. Nelson, A.M. Young, C. Thirlwell i inni. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. „J Clin Oncol”. 23 (22), s. 5224–5228, 2005. DOI: 10.1200/JCO.2005.14.597. PMID: 16051964. 
  • C.J. Achenbach, R.D. Harrington, S. Dhanireddy, H.M. Crane i inni. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. „Clin Infect Dis”. 54 (3), s. 424–433, 2012. DOI: 10.1093/cid/cir802. PMID: 22095568. 
  • R.S. Leidner, D.M. Aboulafia. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. „AIDS Patient Care STDS”. 19 (10), s. 635–644, 2005. DOI: 10.1089/apc.2005.19.635. PMID: 16232048. 
  • E. Régnier-Rosencher, B. Guillot, N. Dupin. Treatments for classic Kaposi sarcoma: a systematic review of the literature. „J Am Acad Dermatol”. 68 (2), s. 313–331, 2013. DOI: 10.1016/j.jaad.2012.04.018. PMID: 22695100. 
  • S.M. Rafiyath, M. Rasul, B. Lee, G. Wei i inni. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. „Exp Hematol Oncol”. 1 (1), s. 10, 2012. DOI: 10.1186/2162-3619-1-10. PMID: 23210520. 
  • D.W. Northfelt, B.J. Dezube, J.A. Thommes, B.J. Miller i inni. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. „J Clin Oncol”. 16 (7), s. 2445–2451, 1998. DOI: 10.1200/jco.1998.16.7.2445. PMID: 9667262. 
  • S. Stewart, H. Jablonowski, F.D. Goebel, K. Arasteh i inni. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. „J Clin Oncol”. 16 (2), s. 683–691, 1998. DOI: 10.1200/jco.1998.16.2.683. PMID: 9469358. 
  • P.S. Gill, J. Wernz, D.T. Scadden, P. Cohen i inni. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. „J Clin Oncol”. 14 (8), s. 2353–2364, 1996. DOI: 10.1200/jco.1996.14.8.2353. PMID: 8708728. 
  • T. Cooley, D. Henry, M. Tonda, S. Sun i inni. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. „Oncologist”. 12 (1), s. 114–123, 2007. DOI: 10.1634/theoncologist.12-1-114. PMID: 17227906. 
  • P.S. Gill, A. Tulpule, B.M. Espina, S. Cabriales i inni. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. „J Clin Oncol”. 17 (6), s. 1876–1883, 1999. DOI: 10.1200/jco.1999.17.6.1876. PMID: 10561228. 
  • L. Welles, M.W. Saville, J. Lietzau, J.M. Pluda i inni. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. „J Clin Oncol”. 16 (3), s. 1112–1121, 1998. DOI: 10.1200/jco.1998.16.3.1112. PMID: 9508198. 
  • M. Cianfrocca, S. Lee, J. Von Roenn, A. Tulpule i inni. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. „Cancer”. 116 (16), s. 3969–3977, 2010. DOI: 10.1002/cncr.25362. PMID: 20564162. 
  • J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles i inni. Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. „Ann Oncol”. 14 (11), s. 1660–1666, 2003. PMID: 14581275. 
  • J. Autier, C. Picard-Dahan, E. Marinho, M. Grossin i inni. Docetaxel in anthracycline-pretreated AIDS-related Kaposi’s sarcoma: a retrospective study. „Br J Dermatol”. 152 (5), s. 1026–1029, 2005. DOI: 10.1111/j.1365-2133.2005.06452.x. PMID: 15888164. 
  • S.T. Lim, A. Tupule, B.M. Espina, A.M. Levine. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. „Cancer”. 103 (2), s. 417–421, 2005. DOI: 10.1002/cncr.20780. PMID: 15578686. 
  • S.E. Krown, P. Li, J.H. Von Roenn, J. Paredes i inni. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi’s sarcoma: a randomized phase II AIDS clinical trials group study. „J Interferon Cytokine Res”. 22 (3), s. 295–303, 2002. DOI: 10.1089/107999002753675712. PMID: 12034036. 
  • F.A. Shepherd, R. Beaulieu, K. Gelmon, C.A. Thuot i inni. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. „J Clin Oncol”. 16 (5), s. 1736–1742, 1998. DOI: 10.1200/jco.1998.16.5.1736. PMID: 9586886. 
  • A. Kreuter, H. Rasokat, M. Klouche, S. Esser i inni. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi’s sarcoma; retrospective analysis of three German centers. „Cancer Invest”. 23 (8), s. 653–659, 2005. DOI: 10.1080/07357900500358259. PMID: 16377582. 
  • D. Hauerstock, W. Gerstein, T. Vuong. Results of radiation therapy for treatment of classic Kaposi sarcoma. „J Cutan Med Surg”. 13 (1). s. 18–21. PMID: 19298767. 
  • G. Di Lorenzo, A. Kreuter, R. Di Trolio, A. Guarini i inni. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi’s sarcoma: a multicenter study. „J Invest Dermatol”. 128 (6), s. 1578–1580, 2008. DOI: 10.1038/sj.jid.5701215. PMID: 18185536. 
  • G. Di Lorenzo. Update on classic Kaposi sarcoma therapy: new look at an old disease. „Crit Rev Oncol Hematol”. 68 (3), s. 242–249, 2008. DOI: 10.1016/j.critrevonc.2008.06.007. PMID: 18657433. 
  • L. Brambilla, A. Romanelli, M. Bellinvia, S. Ferrucci i inni. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. „Br J Dermatol”. 158 (6), s. 1339–1344, 2008. DOI: 10.1111/j.1365-2133.2008.08517.x. PMID: 18363766. 
  • L. Fardet, P.E. Stoebner, H. Bachelez, V. Descamps i inni. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. „Cancer”. 106 (8), s. 1785–1789, 2006. DOI: 10.1002/cncr.21791. PMID: 16534786. 
  • E. Klein, R.A. Schwartz, Y. Laor, H. Milgrom i inni. Treatment of Kaposi’s sarcoma with vinblastine. „Cancer”. 45 (3), s. 427–431, 1980. PMID: 7353196. 
  • L. Brambilla, R. Labianca, V. Boneschi, S. Fossati i inni. Mediterranean Kaposi’s sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. „Cancer”. 74 (10), s. 2873–2878, 1994. PMID: 7954250. 
  • G. Stallone, A. Schena, B. Infante, S. Di Paolo i inni. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. „N Engl J Med”. 352 (13), s. 1317–1323, 2005. DOI: 10.1056/NEJMoa042831. PMID: 15800227. 
  • A. van Kessel, K.D. Quint, M. Kaposi. Moritz Kaposi and his sarcoma. „Ned Tijdschr Geneeskd”. 155 (45), 2011. PMID: 22085570. 
  • R.A. Shiels, M. Kaposi. A history of Kaposi’s sarcoma. „J R Soc Med”. 79 (9), s. 532–534, 1986. PMID: 3534266. 
  • M. Karamanou, C. Antoniou, A.J. Stratigos, Z. Saridaki i inni. The eminent dermatologist Moriz Kaposi (1837–1902) and the first description of idiopathic multiple pigmented sarcoma of the skin. „J BUON”. 18 (4). s. 1101–1105. PMID: 24344048. 

aidsinfo.nih.gov

omicsonline.org

onkologia.org.pl

web.archive.org

who.int

yhscn.nhs.uk